Ownership and insider activity for Codexis, Inc. (CDXS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.
Price
| Price | $1.34 |
| Market Cap | $144M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-17 | PARKER H STEWART | A-Award | 66,350 | $165K |
| 2026-06-17 | Collins Cynthia | A-Award | 66,350 | $165K |
| 2026-06-17 | Richards Christos | A-Award | 66,350 | $165K |
| 2026-06-17 | Smith David V | A-Award | 66,350 | $165K |
| 2026-06-17 | Singhvi Rahul | A-Award | 66,350 | $165K |
| 2026-06-17 | Martinborough Esther | A-Award | 66,350 | $165K |
| 2026-06-17 | DILLY STEPHEN GEORGE | A-Award | 66,350 | $165K |
| 2026-06-17 | De Vre Raymond | A-Award | 66,350 | $165K |
| 2026-06-11 | De Vre Raymond | S-Sale | 2,605 | $6K |
| 2026-02-23 | Lutz Stefan | A-Award | 316,100 | $338K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.2M | $31.2M | $53.0M | $90.5M | $149.1M | $116.8M | $114.0M | $65.1M | $19.3M | $50.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | $1.0M | 0 | 0 | 0 | $54.2M | $27.4M |
| Receivables | $5.9M | $11.8M | $13.5M | $20.2M | $29.3M | $37.7M | $40.9M | $19.9M | $18.9M | $10.7M |
| Inventory | $825000 | $1.0M | $589000 | $371000 | $964000 | $1.2M | $2.0M | $2.7M | $1.8M | $1.8M |
| Total Current Assets | $27.2M | $45.0M | $68.2M | $114.2M | $184.4M | $161.9M | $162.9M | $93.5M | $98.8M | $96.8M |
| Property, Plant & Equipment | $2.2M | $2.8M | $4.8M | $30.4M | $31.2M | $65.5M | $61.9M | $28.6M | $42.9M | $43.5M |
| Goodwill | $3.2M | $3.2M | $3.2M | $3.2M | $3.2M | $3.2M | $3.2M | $2.5M | $2.5M | $2.5M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $35.6M | $53.6M | $79.3M | $149.1M | $221.6M | $246.4M | $250.4M | $136.6M | $149.0M | $147.8M |
| Accounts Payable | $4.2M | $3.5M | $3.0M | $2.6M | $3.0M | $3.0M | $3.2M | $5.9M | $2.8M | $1.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $12.4M | $25.0M | $17.1M | $15.4M | $25.0M | $33.4M | $49.1M | $35.8M | $23.6M | $25.3M |
| Long-term Debt | $885000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $28.9M | $40.1M |
| Total Liabilities | $16.5M | $29.1M | $22.0M | $43.6M | $51.5M | $82.0M | $105.6M | $49.9M | $82.1M | $97.3M |
| Retained Earnings | -$292.1M | -$315.1M | -$330.5M | -$342.4M | -$366.4M | -$387.7M | -$421.3M | -$497.5M | -$562.8M | -$606.8M |
| Total Equity | $19.1M | $24.5M | $56.3M | $105.5M | $170.1M | $164.4M | $144.8M | $86.6M | $66.9M | $50.5M |
| Total Debt | $425000 | $302000 | $303000 | $26.1M | $25.0M | $47.7M | $43.6M | $16.0M | $59.9M | $73.2M |
| Net Debt | -$18.8M | -$30.9M | -$52.7M | -$64.4M | -$125.2M | -$69.1M | -$70.3M | -$49.1M | -$13.6M | -$5.0M |
| Working Capital | $14.9M | $20.1M | $51.1M | $98.8M | $159.4M | $128.5M | $113.8M | $57.6M | $75.1M | $71.5M |
Financial Health
| Debt / Equity | 2.20 |
| Current Ratio | 3.06 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -4.67 |
Profitability
| Return on Equity | -74.36% |
| Return on Invested Capital | -22.69% |
| Return on Assets | -25.59% |
| Gross Margin | 83.71% |
| Operating Margin | -31.23% |
| Net Margin | -39.55% |
Related companies: ARMP · CCCC · GNFT · IMDX · IPHA · IVVD · OABI
Explore sector: Healthcare · Biotechnology
More sections of CDXS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks